Immunomedics CEO Michael Pehl Resigns

Michael Pehl has resigned as CEO of Immunomedics (NASDAQ: [[ticker:IMMU]]), 15 months after he left Celgene (NASDAQ: [[ticker:CELG]]) to take the top job at the Morris Plains, NJ, company. In a press release, Immunomedics says Pehl is returning to Europe. According to a securities filing, Pehl will remain an Immunomedics employee for 30 days to help with the transition of his responsibilities. The announcement comes a month after the FDA rejected Immunomedics triple negative breast cancer drug sacituzumab govitecan due to manufacturing problems.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan